UK Curaleaf Laboratories Enters Strategic Partnership with ANTG to Manufacture and Distribute Medicinal Cannabis Products in the UK

Curaleaf Laboratories, one of the UK’s leading providers of medicinal cannabis products, is pleased to announce a landmark partnership with Australian Natural Therapeutics Group (ANTG), one of Australia’s most respected producers of pharmaceutical-grade medicinal cannabis.

Under this agreement, Curaleaf Laboratories will manufacture and distribute ANTG’s range of products across the United Kingdom, significantly expanding access to medicinal cannabis for eligible patients and healthcare professionals.

The partnership combines Curaleaf Laboratories’ state-of-the-art UK manufacturing capabilities and established distribution network with ANTG’s expertise in cultivating and developing consistent, pharmaceutical-grade cannabis formulations.

Together, the companies aim to meet the growing demand for safe, effective, and reliably sourced medicinal cannabis products in the UK market, in line with applicable regulations.

SOMAÍ Adds International Lifestyle Brand Cookies to Global Medical Cannabis Markets ​

Read More »
November 12, 2025 No Comments

Plans to Ban Intoxicating Hemp Take Center Stage in Battle to Reopen US Government ​

Read More »
November 11, 2025 No Comments

The Evidence Pyramid: Understanding Cannabis Research ​

Read More »
November 11, 2025 No Comments

Richard Hodgson, Managing Director, Curaleaf Laboratories, said:

“This partnership marks a significant milestone for Curaleaf Laboratories as we continue to deliver on our commitment to support patient access to pharmaceutical-grade, evidence-based cannabis medicines.”

“ANTG’s reputation for excellence and scientific rigor aligns perfectly with our mission to set new standards in product quality and patient care.”

Matt Cantelo, Founder and CEO, ANTG added:

“Partnering with Curaleaf Laboratories brings together two organisations dedicated to quality and patient care. This collaboration represents an important step in our international growth strategy and our shared goal of improving patient outcomes through trusted, pharmaceutical-grade cannabis-based medicines.”

The first ANTG products manufactured under this partnership will be available on prescription by clinicians listed on the UK Specialist Register from November 2025.

If you are an interested healthcare professional seeking information on prescribing or ordering, please contact us at info@curaleaflaboratories.co.uk

Patients seeking information from their dispensing pharmacy may visit Curaleaf Pharmacy if applicable. Treatment decisions should be made in consultation with a qualified healthcare professional.

The post Curaleaf Laboratories Enters Strategic Partnership with ANTG to Manufacture and Distribute Medicinal Cannabis Products in the UK appeared first on Business of Cannabis.

Continue reading...